TNF receptor-associated factor 5 (TRAF5) is a crucial adapter molecule that plays a significant role in the signal transduction pathways of the tumor necrosis factor receptor (TNFR) superfamily and the interleukin-1 receptor/Toll-like receptor (IL-1R/TLR) superfamily. It is implicated in the regulation of various cellular processes including the activation of NF-κB and MAP kinases, which are pivotal for immune responses, inflammation, cell survival, and proliferation. TRAF5 achieves these regulatory roles through its ability to mediate signal transduction by interacting with receptor complexes and upstream signaling molecules. It operates by directly binding to the receptors or to other TRAF molecules, facilitating the recruitment of downstream signaling components. This interaction promotes the activation of transcription factors such as NF-κB, which then translocate to the nucleus to initiate the transcription of genes involved in immune and inflammatory responses. The significance of TRAF5 in signaling pathways underscores its role in maintaining cellular homeostasis and its involvement in the innate and adaptive immune responses.
The inhibition of TRAF5 involves the disruption of its ability to mediate signal transduction in the NF-κB and MAP kinase pathways. This can be achieved through various mechanisms, including the prevention of TRAF5's interaction with its receptor complexes or upstream signaling molecules, thereby hindering its capacity to initiate downstream signaling events. Inhibition can also occur through the disruption of TRAF5's E3 ubiquitin ligase activity, which is essential for the polyubiquitination of target proteins that are critical for the activation of signaling pathways. Additionally, the competitive binding of inhibitors to the TRAF domain of TRAF5, which is responsible for its interaction with other signaling proteins, can effectively block the assembly of signaling complexes. This interference with TRAF5's functional domains prevents the propagation of signals required for the activation of transcription factors and the expression of genes involved in inflammatory and immune responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
p53 Activator III, RITA | 213261-59-7 | sc-202753 sc-202753A sc-202753B sc-202753C | 1 mg 10 mg 100 mg 500 mg | $110.00 $268.00 $1533.00 $5103.00 | 9 | |
RITA is a chemical compound that indirectly inhibits TRAF5 through inhibition of the NF-κB pathway. It disrupts the activation of NF-κB, a downstream target of TRAF5, leading to reduced TRAF5-dependent signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that indirectly inhibits TRAF5 by preventing the degradation of IκB (Inhibitor of κB). This stabilizes IκB and inhibits the NF-κB pathway, which is regulated by TRAF5. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $210.00 $252.00 $1740.00 $1964.00 | 34 | |
This compound, also called JSH-23, is an inhibitor of the nuclear translocation of NF-κB p65. By preventing the nuclear translocation of p65, JSH-23 indirectly suppresses the NF-κB pathway, which is regulated by TRAF5. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $260.00 $925.00 | 5 | |
C646 is a small molecule inhibitor of CBP/p300 histone acetyltransferases. It indirectly inhibits TRAF5 by preventing the acetylation of NF-κB p65, which impairs the transcriptional activity of p65 and, consequently, NF-κB signaling regulated by TRAF5. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN4924 is an NEDD8-activating enzyme (NAE) inhibitor that indirectly affects TRAF5 activity. It modulates the neddylation pathway, which can influence NF-κB signaling, a pathway regulated by TRAF5. | ||||||
TH-302 | 918633-87-1 | sc-364635 sc-364635A | 5 mg 50 mg | $225.00 $1700.00 | 1 | |
TH-302 is a hypoxia-activated prodrug that indirectly inhibits TRAF5 by targeting the hypoxia response pathway. It can affect HIF-1α (Hypoxia-Inducible Factor 1-alpha) stability and, subsequently, influence TRAF5-mediated signaling under hypoxic conditions. | ||||||
MRT67307 | 1190378-57-4 | sc-507433 | 10 mg | $234.00 | ||
MRT67307 is a dual IKKε/TBK1 (IκB Kinase epsilon/TANK-Binding Kinase 1) inhibitor. It indirectly inhibits TRAF5 since IKKε and TBK1 are kinases upstream of TRAF5 in certain signaling pathways. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $127.00 $572.00 $4090.00 $20104.00 | 20 | |
Withaferin A is a natural compound that indirectly inhibits TRAF5 by targeting the NF-κB pathway. It can interfere with the activation of NF-κB, a downstream target of TRAF5, leading to reduced TRAF5-dependent signaling. | ||||||